医療機器リーダーシリーズ：体外診断用医療機器（IVD）の上位企業2017-2027...市場調査レポートについてご紹介

1. Report Overview
1.1 How This Report Delivers Information
1.2 Main Questions This Report Answers
1.3 Who is This Report For?
1.4 Methods of Research and Analysis
1.5 Frequently Asked Questions (FAQs)
1.6 Some Related Reports
1.7 About Visiongain

2. An Introduction to In Vitro Diagnostics
2.1 The In Vitro Diagnostics Market
2.1.1 The In Vitro Diagnostics Market in 2017
2.2 What are In Vitro Diagnostic (IVD) Tests?
2.3 Classifying In Vitro Diagnostics
2.3.1 The US Classification
2.3.2 The EC (European Commission) Classification
2.3.3 Regulatory Issues in the IVD Market
2.3.3.1 Regulation of IVD Tests
2.3.3.2 Lack of Clarity Can be Costly
2.4 Types of IVD Test
2.4.1 Point of Care Diagnostics
2.4.2 Clinical Chemistry
2.4.3 Microbiology
2.4.3.1 Regulatory Differences with IVD Microbiology Tests
2.4.4 Haematology
2.4.5 Immunochemistry
2.4.6 Genetic Testing
2.5 The IVD Market: Overall Revenue Forecast to 2027
2.5.1 Market Drivers, 2016-2027
2.5.2 Market Restraints, 2016-2027
2.5.3 Future of the IVD Industry
2.6 Company Comparison
2.6.1 Fragmented Market
2.6.2 IVD Market: Leading Manufacturers in 2016

3. The Leading US In Vitro Diagnostic Companies, 2016-2027
3.1 Danaher
3.1.1 Sales and Recent Performance Analysis
3.1.2 Life Sciences and Diagnostics
3.1.3 Key Products
3.1.4 Danaher Manufacturing Capabilities
3.1.5 Danaher IVD Segment: Strengths and Challenges
3.1.6 Danaher’s Life Sciences and Diagnostics Revenues
3.1.6.1 IVD Revenue Forecast, 2016-2027
3.1.7 Recent Mergers and Acquisition (M&A) Activity
3.2 Abbott Laboratories
3.2.1 Sales and Recent Performance Analysis
3.2.2 Abbott: Diagnostics Segment
3.2.2.1 In Vitro Diagnostics Products
3.2.3 Abbott IVD Segment: Strengths and Challenges
3.2.4 Abbott Diagnostics Historical Revenues, 2013-2015
3.2.5 IVD Revenue Forecast, 2016-2027
3.2.6 Recent M&A Activity and Strategic Collaborations
3.2.6.1 Collaboration with GSK
3.2.6.2 Collaboration with Merck
3.2.6.3 Acquisition of STARLIMS Technologies
3.2.6.4 Acquisition of Ibis Biosciences, Inc.
3.2.7 Plans to Separate into Two Publicly Traded Companies
3.3 Johnson & Johnson (J&J)
3.4 Bio-Rad
3.4.1 Sales and Recent Performance Analysis
3.4.2 Clinical Diagnostics
3.4.2.1 In Vitro Diagnostics
3.4.3 IVD Revenue 2015
3.4.4 IVD Revenue Forecast, 2017-2026
3.4.5 Recent M&A Activity and Strategic Collaborations
3.4.6 Potential Bio-Rad Labs Takeover Seen in Near-Term
3.5 Becton Dickinson
3.5.1 Global Presence
3.5.2 Distribution
3.5.3 R&D
3.5.4 Sales and Recent Performance Analysis
3.5.4.1 Historical Sales Performance Analysis
3.5.5 BD Diagnostics Revenue
3.5.6 IVD Revenue Forecast, 2017-2027
3.5.7 Recent M&A Activity and Strategic Collaborations
3.6 Thermo Fisher Scientific
3.6.1 Historical Sales and Recent Performance Analysis
3.6.2 Clinical Diagnostics
3.6.3 Key Products
3.6.4 Thermo Fisher’s Manufacturing Capabilities
3.6.5 Thermo Fisher’s Diagnostics Revenues
3.6.6 IVD Revenue Forecast 2016-2027
3.6.7 Recent Mergers and Acquisition Activity
3.6.7.1 Acquisition of Dionex and Phadia

4. The Leading European In Vitro Diagnostic Companies, 2016-2027
4.1 Roche
4.1.1 Global Presence
4.1.2 Sales and Recent Performance Analysis
4.1.3 Roche Diagnostics
4.1.4 R&D Capabilities
4.1.5 Growing Portfolio of Diagnostic Products
4.1.5.1 Exploring Strategies in the Neurological Sector
4.1.6 IVD Revenue Forecast 2016-2027
4.1.7 Recent M&A Activity and Strategic Collaborations
4.1.7.1 Roche Offers to Acquire Illumina to Strengthen its Leading Position in Diagnostics
4.2 Siemens
4.2.1 Sales and Recent Performance, 2015
4.2.2 Siemens Healthcare
4.2.2.1 Siemens Diagnostics
4.2.2.2 Outperforming the Market
4.2.2.3 In Vitro Diagnostics
4.2.3 IVD Revenue Forecast 2016-2027
4.2.4 Recent M&A Activity and Strategic Collaborations
4.2.4.1 Partnership with ViiV Healthcare
4.2.4.2 Partnership with Tocagen
4.3 bioMérieux
4.3.1 Sales and Recent Performance, 2015
4.3.2 IVD Revenue Forecast 2016-2027
4.3.3 Recent M&A Activity and Strategic Collaborations
4.3.3.1 Partnership with GSK
4.3.3.2 Partnership with Ipsen
4.3.3.3 Partnership with Institute Merieux and Institute Pasteur
4.3.3.4 Collaboration with Hospices Civils de Lyon
4.3.3.5 Acquisition of ARGENE
4.3.3.6 Equity Interest in Knome

5. The Leading Japanese In Vitro Diagnostic Companies, 2016-2027
5.1 Sysmex
5.1.1 Global Presence and Distribution
5.1.2 Sales and Recent Performance Analysis
5.1.3 Sysmex Diagnostics
5.1.4 IVD Revenue Forecast 2016-2027
5.1.5 Recent M&A Activity and Strategic Collaborations
5.1.5.1 Acquisition of Katakura’s Research Institute of Biological Science
5.1.5.2 Collaboration with IDEXX Labs to Expand into Animal Diagnostics
5.2 Arkray
5.2.1 Global Presence
5.2.2 R&D
5.2.3 IVD Product Portfolio
5.2.4 Sales and Recent Performance Analysis
5.2.5 IVD Revenue Forecast 2016-2027

6. Emerging In Vitro Diagnostic Companies, 2017
6.1 Pipeline and Other Companies: An Overview, 2017
6.2 Other Prominent In Vitro Diagnostic Players
6.3 Dako (Agilent Technologies)
6.3.1 Sales and Recent Performance Analysis
6.3.2 M&A Activity and Other Key Developments
6.4 Genomic Health
6.4.1 Sales and Recent Performance Analysis
6.4.2 R&D Capabilities
6.4.2.1 TAILORx Clinical Trial
6.4.2.2 RxPonder Trial
6.4.2.3 Partnership with Oncomed
6.5 Laboratory Corporation of America (LabCorp)
6.5.1 Sales and Recent Performance Analysis
6.5.2 In Vitro Diagnostics
6.6 Recent M&A Activity and Other Key Developments
6.6.1 Agreement with Medco Health Sciences
6.6.2 Acquisition of Monogram Biosciences
6.6.3 Non-Exclusive License Agreement with Merck
6.6.4 Acquisition of Genzyme Genetics
6.6.5 Partnership with ARCA Biopharma
6.7 MDxHealth
6.7.1 Sales and Recent Performance Analysis, 2015
6.7.2 R&D Capabilities
6.7.3 In Vitro Diagnostics
6.7.3.1 PharmacoMDx
6.7.3.2 PredictMDx for Brain Cancer
6.7.3.3 PredictMDx for Colon Cancer
6.7.3.4 Partnership with GSK
6.8 Myriad Genetics
6.8.1 Sales and Recent Performance Analysis
6.8.2 R&D Capabilities
6.8.3 In Vitro Diagnostics
6.8.3.1 Myriad RBM
6.8.4 M&A Activity and Recent Partnerships
6.8.4.1 Agreement with BioMarin Pharmaceutical
6.8.4.2 Acquisition of Myriad RBM
6.8.4.3 Strategic Debt Investment in Crescendo Bioscience
6.8.4.4 Agreement with Cephalon
6.8.4.5 Agreement with PharmaMar
6.9 QIAGEN
6.9.1 Sales and Recent Performance Analysis
6.9.2 Continued Expansion in the Emerging Markets
6.9.3 R&D Capabilities
6.9.3.1 More than 15 Projects to Co-Develop and Market Diagnostic Products
6.9.3.2 Provider of Choice for Molecular Diagnostic Tools
6.9.4 Recent M&A Activity and Other Developments
6.9.4.1 Acquisition of Cellestis Ltd.
6.9.4.2 Acquisition of Ipsogen
6.9.4.3 Partnership with Pfizer
6.9.4.4 Partnership with Eli Lilly
6.9.4.5 Acquisition of SABiosciences Corporation
6.9.4.6 Acquisition of DxS Ltd (Now QIAGEN Manchester)
6.9.4.7 Acquisition of Explera s.r.l

7. Conclusions
7.1 In Vitro Diagnostics: Attractive Segment of the Healthcare Market
7.2 Big Pharma Dominated the IVD Market in 2015
7.3 The Rise of ‘Generic Medical Devices’
7.4 What Will Succeed in the IVD Market?
7.5 Small Companies Can Have a Big Impact on the Industry and Market to 2027

Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form